Companion Diagnostics Market Size, Share and Growth Outlook, 2026

Companion Diagnostics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Companion Diagnostics Market size is forecast to increase from $9.99 Billion in 2026 to $25.45 Billion in 2034 at a CAGR of 12.4% between 2026 and 2034.

The Companion Diagnostics market report provides detailed analysis and outlook of Companion Diagnostics segments including By Product & Service (Assays and Kits, Instruments and Analyzers, Software and Services), By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Immunohistochemistry, In Situ Hybridization, Liquid Biopsy), By Indication (Oncology, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders, Autoimmune Disorders), By End User (Pharmaceutical and Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations, Hospitals and Diagnostic Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Companion Diagnostics Industry Overview

Artificial Intelligence and Multiomics Technologies Advancing Companion Diagnostics

The companion diagnostics industry is undergoing rapid transformation through the integration of artificial intelligence, digital pathology, and multiomics technologies. Industry stakeholders are increasingly focusing on AI-enabled companion diagnostic platforms to improve biomarker discovery, patient stratification, and therapeutic response prediction. Major scientific forums, including the Next Generation Dx Summit, are highlighting the emergence of digital pathology tools and algorithmic biomarkers derived from multiomics datasets. These technologies enable more precise identification of patient subgroups that are most likely to benefit from targeted therapies. The growing adoption of AI-driven analytical systems is supporting the evolution of precision medicine by enhancing diagnostic accuracy, reducing variability in interpretation, and enabling more individualized treatment decisions across oncology and other therapeutic areas.

Regulatory Approvals Strengthening Precision Oncology Applications

Regulatory agencies continue to support the expansion of companion diagnostics through approvals that directly link diagnostic testing with targeted therapeutic interventions. A significant milestone was achieved when Agilent Technologies received FDA approval for the PD-L1 IHC 22C3 pharmDx assay as a companion diagnostic for esophageal and gastroesophageal junction carcinoma patients eligible for pembrolizumab therapy. This approval reinforces the growing trend of pairing advanced diagnostic assays with immunotherapies to improve treatment selection and clinical outcomes. Agilent further strengthened its position in precision oncology through FDA premarket approval of the Agilent MMR IHC panel pharmDx operating on the Dako Omnis platform. The system is indicated for identifying colorectal cancer patients eligible for specific targeted treatments and subsequently secured European IVDR certification, expanding its regulatory and commercial footprint across key healthcare markets.

AI-Driven Oncology Diagnostics and Integrated Therapeutic Partnerships Expanding Market Scope

Innovation within the companion diagnostics industry is increasingly centered on integrating diagnostics directly into therapeutic development programs. Roche announced continued progress in developing its AI-driven immunohistochemistry companion diagnostic for non-small cell lung cancer. The platform combines digital pathology slides, automated staining instruments, and an artificial intelligence algorithm to evaluate TROP2 expression and deliver highly accurate patient stratification for precision therapies. The technology previously secured FDA Breakthrough Device Designation and is currently available for research use while regulatory preparations continue for full clinical commercialization. In another major development, Regeneron Pharmaceuticals and Telix Pharmaceuticals established a strategic partnership valued at up to $2.14 billion to co-develop and co-commercialize next-generation radiopharmaceutical therapies targeting solid tumors. A central component of the collaboration involves the co-development of companion diagnostics designed to enable real-time assessment of therapeutic responses and support precise patient selection before radiopharmaceutical treatment. These developments demonstrate the increasing convergence of diagnostics, artificial intelligence, targeted therapies, and precision oncology within the global companion diagnostics industry.

Companion Diagnostics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Companion Diagnostics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Qiagen N.V., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, BioMérieux SA, Myriad Genetics, Inc., Sysmex Corporation. The Companion Diagnostics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Companion Diagnostics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Companion Diagnostics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Companion Diagnostics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Companion Diagnostics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Companion Diagnostics Market Competitive Benchmarking and Company Analysis

Leading companies in Companion Diagnostics industry include- F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Qiagen N.V., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, BioMérieux SA, Myriad Genetics, Inc., Sysmex Corporation. The Companion Diagnostics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Companion Diagnostics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Companion Diagnostics market remains one of the strongest-performing segments in the country.
The US Companion Diagnostics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Companion Diagnostics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Companion Diagnostics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Companion Diagnostics markets

Canada's strong Companion Diagnostics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Companion Diagnostics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Companion Diagnostics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Companion Diagnostics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Companion Diagnostics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Companion Diagnostics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Companion Diagnostics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Companion Diagnostics sales through 2034

France Companion Diagnostics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Companion Diagnostics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Companion Diagnostics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Companion Diagnostics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Companion Diagnostics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Companion Diagnostics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Companion Diagnostics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Companion Diagnostics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Companion Diagnostics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Companion Diagnostics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Companion Diagnostics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Companion Diagnostics Market Segmentation

By Product & Service
Assays and Kits
Instruments and Analyzers
Software and Services
By Technology
Polymerase Chain Reaction
Next-Generation Sequencing
Immunohistochemistry
In Situ Hybridization
Liquid Biopsy
By Indication
Oncology
Infectious Diseases
Cardiovascular Diseases
Neurological Disorders
Autoimmune Disorders
By End User
Pharmaceutical and Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations
Hospitals and Diagnostic Centers

Top Companies in Companion Diagnostics Industry

F. Hoffmann-La Roche Ltd.
Agilent Technologies, Inc.
Qiagen N.V.
Abbott Laboratories
Thermo Fisher Scientific Inc.
Illumina, Inc.
Danaher Corporation
BioMérieux SA
Myriad Genetics, Inc.
Sysmex Corporation

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025